Australië - Engels - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - granisetron hydrochloride, quantity: 1.12 mg/ml (equivalent: granisetron, qty 1 mg/ml) - injection, concentrated - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; citric acid monohydrate; water for injections - prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy in adults and children. prevention of nausea and vomiting induced by radiotherapy in adults only. prevention and treatment of post-operative nausea and vomiting in adults only.

Verenigde Staten - Engels - NLM (National Library of Medicine)

auromedics pharma llc - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg in 1 ml - granisetron hydrochloride injection, usp  is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - the prevention and treatment of postoperative nausea and vomiting in adults. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection usp is recommended even where the incidence of postoperative nausea and/or vomiting is low.  granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. teratogenic effects p regnancy category b reproduction studies have been performed in pregnant rat

Verenigde Staten - Engels - NLM (National Library of Medicine)

akorn - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 0.1 mg in 1 ml - granisetron hydrochloride injection, usp is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. pregnancy category b reproduction studies have been performed in pregnant rats at intravenous doses up to 9 mg/kg/day (54 mg/m2 /day, 146 times the recommended human dose based on body surface area) and pregnant rabbits at intravenous doses up to 3 mg/kg/day (35.4 mg/m2 /day, 96 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to granisetron. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive

Verenigde Staten - Engels - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg - granisetron hydrochloride tablets are indicated for the prevention of: granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - granisetron hydrochloride, quantity: 1.12 mg (equivalent: granisetron, qty 1 mg) - injection - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide; sodium chloride; citric acid monohydrate - adults: granisetron injection is indicated for use in adults for:,the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy;,the prevention of nausea and vomiting induced by radiotherapy.,granisetron injection is also indicated for use in the prevention and treatment of post-operative nausea and vomiting.,children: granisetron injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - granisetron hydrochloride, quantity: 3.36 mg (equivalent: granisetron, qty 3 mg) - injection - excipient ingredients: citric acid monohydrate; hydrochloric acid; sodium hydroxide; sodium chloride; water for injections - adults: granisetron injection is indicated for use in adults for:,the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy;,the prevention of nausea and vomiting induced by radiotherapy.,granisetron injection is also indicated for use in the prevention and treatment of post-operative nausea and vomiting.,children: granisetron injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Verenigde Staten - Engels - NLM (National Library of Medicine)

fresenius kabi usa, llc - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg in 1 ml - granisetron hydrochloride injection, usp is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - the prevention and treatment of postoperative nausea and vomiting in adults. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection, usp is recommended even where the incidence of postoperative nausea and/or vomiting is low. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. pregnancy category b reproduction studies have been performed in pregnant rats at intravenous doses up to

Australië - Engels - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - granisetron hydrochloride, quantity: 3.36 mg (equivalent: granisetron, qty 3 mg) - injection, concentrated - excipient ingredients: sodium chloride; hydrochloric acid; water for injections; citric acid monohydrate; sodium hydroxide - adults: granisetron sandoz injection is indicated for use in adults for: - the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy; - the prevention of nausea and vomiting induced by radiotherapy. children: granisetron sandoz injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - granisetron hydrochloride, quantity: 1.12 mg (equivalent: granisetron, qty 1 mg) - injection, solution - excipient ingredients: sodium chloride; citric acid monohydrate; sodium hydroxide; hydrochloric acid; water for injections - adults: granisetron sandoz injection is indicated for use in adults for: - the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy; - the prevention of nausea and vomiting induced by radiotherapy. children: granisetron sandoz injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Verenigde Staten - Engels - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg - granisetron hydrochloride usp is indicated for the prevention of: - nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride usp is contraindicated in patients with known hypersensitivity to the drug or any of its components.